Developer docs
API playgroundTry for free, no card

Search company profiles

MediPharm Labs

Full company profile

uuid0003xaf

Namestring
MediPharm Labs
Legal namestring
MediPharm Labs Corp.
Company typeenum
Public
Founded yearint
2017
Descriptiontext

MediPharm Labs Corp. is a Canadian pharmaceutical-grade cannabis extraction and manufacturing company headquartered in Barrie, Ontario. Founded in 2017 and listed on the TSX under the ticker LABS, the company operates a 70,000 sq. ft. GMP-certified manufacturing facility with ISO cleanrooms and holds the first Drug Establishment License issued in North America for cannabis-based APIs and pharmaceutical drug products. Its core technology stack is supercritical CO2 extraction paired with short-path wiped-film distillation (capable of >80% purity) and centrifugal partition chromatography for cannabinoid isolation, producing pharmaceutical-grade cannabis inputs rather than commodity-grade extracts.

The company operates a multi-channel B2B and B2C business model. Revenue streams include (1) bulk wholesale GMP cannabis API (concentrates, distillates, isolates) sold to licensed producers, pharma, cosmetics, food and beverage, and nutraceutical companies on quote-based multi-year contracts; (2) white label extraction, distillation, formulation, and packaging services; (3) branded consumer products (oils, soft chews, capsules, vapes, metered-dose inhalers) distributed through Canadian provincial retailers and medical cannabis channels; and (4) GMP-certified clinical trial materials supplied to academic and research institutions. Pricing for B2B is quote-based while consumer pricing is set by provincial retailers.

MediPharm distributes internationally through channel partners in 10 countries including Australia, Germany (Beacon Medical, Wildlife), France, Brazil, New Zealand, and Costa Rica (Remidose LATAM). The April 2023 all-equity acquisition of VIVO Cannabis expanded the combined entity to over CA$50M in annual revenue and added the Beacon Medical and Wildlife brands for international markets. As of Q1 2026, international medical cannabis represented 56% of total revenue and was growing 83% year-over-year. The company employs 101-250 staff, is virtually debt-free with $9.9M in cash, and recently achieved positive adjusted EBITDA under a newly appointed interim CEO.

Short descriptiontext

MediPharm Labs is a Canadian GMP-certified pharmaceutical cannabis extraction and manufacturing company that produces cannabinoid APIs, white-label products, and branded consumer goods for licensed producers, provincial retailers, and international medical markets across 10 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBarrie, Canada
HQ citystring
Barrie
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cannabis extraction services, pharmaceutical cannabis manufacturing, GMP-certified cannabis API, white label cannabis production, medical cannabis distribution
Industry2 codes
PRIMARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Pharmaceutical Cannabis Manufacturing
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1GMP Cannabis API Wholesale
TypeOne Time License
Description

Bulk wholesale offerings including concentrate, distillate, and isolate products in various cannabinoid ratios sold to licensed producers, pharmaceutical companies, cosmetics, food & beverage, and nutraceutical companies.

medipharmlabs.com
2White Label Production
TypeProfessional Services
Description

Custom extraction, distillation, formulation, sensory testing, packaging, labelling, and distribution services for white label clients including licensed producers.

medipharmlabs.com
3Branded Consumer Products
TypeOne Time License
Description

Pharma-quality branded products including formulated oils (CBD25, CBD50, CBD100, THC30, CBN1:2), soft chews, capsules, vapes, and inhalers sold through Canadian provincial retailers and medical channels.

medipharmlabs.com
4Clinical Trial Materials
TypeProfessional Services
Description

Supply of GMP-certified cannabis products for clinical trials including regulatory support documentation for Health Canada and international clinical trial applications.

globenewswire.com
5International Medical Cannabis
TypeOne Time License
Description

Export of GMP-certified medicinal cannabis products including oils, tinctures, metered dose inhalers, and dried flower to international markets including Australia, Germany, France, Brazil, New Zealand, and Costa Rica.

globenewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details2 tiers
1B2B wholesale and white label production services
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing for bulk wholesale cannabis API, white label production, and custom formulations. Pricing varies by product type, volume, and specification requirements.

medipharmlabs.com
2Branded consumer products through provincial retailers
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Consumer products including oils, soft chews, capsules, vapes, and inhalers sold through provincial retailers. Retail pricing set by individual provincial retailers.

medipharmlabs.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Beacon Medical
Description

Medical cannabis brand serving international markets including Germany and New Zealand

medipharmlabs.com
+1 more record
Core offering1 text field

MediPharm Labs is a pharmaceutical manufacturer specializing in GMP-certified cannabis extraction, purification, and formulation, producing bulk wholesale cannabinoid active pharmaceutical ingredients (API), distillates, and isolates. The company offers white label extraction, distillation, formulation, packaging, and distribution services to licensed producers, and sells its own branded line of formulated oils, soft chews, capsules, vapes, and metered-dose inhalers through Canadian provincial retailers and international medical cannabis channels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • First Drug Establishment License holder in North America for cannabis API sales
+3 more records
Product and service3 records
1GMP Cannabis API
CategoryCannabis API / Bulk Ingredients
2White Label Cannabis Production
CategoryContract Manufacturing / White Label
3MediPharm Labs Branded Consumer Cannabis Products
Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Remidose LATAM SRL
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-13
Description

Definitive supply agreement for export of GMP-certified medicinal cannabis products including oils, tinctures, metered dose inhalers, and dried flower into Costa Rica's newly opened medical cannabis market. Remidose LATAM holds full licensing and authorization from Costa Rican health authorities. Costa Rica's market is projected to exceed US$35 million annually.

tipranks.com
2International Medicinal Cannabis Organization
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-04
Description

Production agreement with an international medicinal cannabis organization for MediPharm's first shipment to France, marking entry into Europe's emerging medical cannabis market. The agreement enables MediPharm to meet strict European regulatory standards while expanding global footprint.

manilatimes.net
3VIVO Cannabis Inc.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-04-01
Description

MediPharm Labs completed acquisition of VIVO Cannabis Inc. in an all-equity transaction, creating a combined entity with expanded international and Canadian market presence. The ownership ratio is approximately 73.1% for MediPharm shareholders and 26.9% for VIVO shareholders. Deal includes integration of VIVO's brands and operations with targeted annual synergies of CA$7-9 million.

newswire.ca
Strategic tierCoreTypeStrategic or Co-development Partner
Description

MediPharm Labs has partnered with McMaster University for multiple approved clinical trials in indications including depression-related sleep disorders, post-surgical pain treatment, and opioid sparing in chronic pain. The partnership includes provision of clinical trial materials with regulatory support documentation for Health Canada submissions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership with Toronto's University Health Network leveraging MediPharm's pharmaceutical experience with leading healthcare professionals researching cannabis-derived therapies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

4-year partnership commitment with Loyalist College including access to applied research opportunities, donation of $100,000 of cannabis derivatives towards study, hiring of interns, and hosting annual cohort for educational lectures. Advancing understanding of cannabis-based medicines.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Partnership with German distributors Beacon Medical and Wildlife for product portfolio expansion in Germany, supporting 14% sequential revenue growth in Q1 2026.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Canadian cannabis producer with global medical cannabis operations and CPG brands. Comparable on GMP manufacturing, branded consumer products, and international distribution, though it is in restructuring and significantly larger than MediPharm.

2Tilray Brands
TypeBroad incumbent
Description

Large multi-jurisdiction cannabis operator with cultivation, processing, branded products, and pharma exposure (including Manitoba Harvest and medical cannabis). Comparable to MediPharm on cannabis manufacturing and international medical distribution, though at far greater scale and with a wider product portfolio.

TypeBroad incumbent
Description

Major Canadian licensed producer with GMP-certified cultivation, processing, and a focus on medical cannabis across Canada and Europe. Comparable on GMP manufacturing, medical cannabis focus, and international regulatory expertise.

TypeDirect peer
Description

Canadian licensed producer with GMP-certified manufacturing, branded consumer products, and international medical cannabis operations. Closely comparable in scale, GMP positioning, and medical/consumer split.

TypeBroad incumbent
Description

Canadian cannabis operator with international footprint and a focus on branded products and cannabinoid research, including a strategic partnership with Altria. Comparable on GMP operations and international medical distribution, though more consumer-brand focused.

TypeDirect peer
Description

Canadian cannabis extraction specialist and white-label manufacturer producing cannabis concentrates, infused beverages, and pharma-grade products. Directly comparable on extraction-led business model, white label services, and B2B cannabis API offerings.

7VIVO Cannabis (now part of MediPharm)
TypeDirect peer
Description

Canadian licensed producer with Canna Farms medical brand and Beacon Medical/Wildlife international brands. Acquired by MediPharm in 2023; now a subsidiary providing direct comparability on cultivation, branded products, and international medical distribution.

TypeBroad incumbent
Description

Owns Epidiolex, the first FDA-approved plant-derived cannabinoid prescription drug, and operates GMP-grade cannabis botanical drug substance manufacturing. Comparable on pharma-grade cannabinoid drug manufacturing and clinical/commercial regulatory pathways.

TypeDirect peer
Description

CBD-focused branded cannabis wellness products company with cultivation, extraction, and consumer product lines. Comparable on extraction-to-product manufacturing model and branded CBD/THC product portfolio in regulated markets.

TypeDirect peer
Description

Multi-jurisdiction cannabis operator focused on GMP-certified cultivation, extraction, and B2B API/finished product supply to international markets including Europe, Latin America, and Australia. Closely comparable on B2B pharma-grade cannabis API model and international medical distribution.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MediPharm Labs

Pharmaceutical Cannabis Manufacturingmedipharmlabs.com

MediPharm Labs is a Canadian GMP-certified pharmaceutical cannabis extraction and manufacturing company that produces cannabinoid APIs, white-label products, and branded consumer goods for licensed producers, provincial retailers, and international medical markets across 10 countries.

What MediPharm Labs does

MediPharm Labs Corp. is a Canadian pharmaceutical-grade cannabis extraction and manufacturing company headquartered in Barrie, Ontario. Founded in 2017 and listed on the TSX under the ticker LABS, the company operates a 70,000 sq. ft. GMP-certified manufacturing facility with ISO cleanrooms and holds the first Drug Establishment License issued in North America for cannabis-based APIs and pharmaceutical drug products. Its core technology stack is supercritical CO2 extraction paired with short-path wiped-film distillation (capable of >80% purity) and centrifugal partition chromatography for cannabinoid isolation, producing pharmaceutical-grade cannabis inputs rather than commodity-grade extracts.

The company operates a multi-channel B2B and B2C business model. Revenue streams include (1) bulk wholesale GMP cannabis API (concentrates, distillates, isolates) sold to licensed producers, pharma, cosmetics, food and beverage, and nutraceutical companies on quote-based multi-year contracts; (2) white label extraction, distillation, formulation, and packaging services; (3) branded consumer products (oils, soft chews, capsules, vapes, metered-dose inhalers) distributed through Canadian provincial retailers and medical cannabis channels; and (4) GMP-certified clinical trial materials supplied to academic and research institutions. Pricing for B2B is quote-based while consumer pricing is set by provincial retailers.

MediPharm distributes internationally through channel partners in 10 countries including Australia, Germany (Beacon Medical, Wildlife), France, Brazil, New Zealand, and Costa Rica (Remidose LATAM). The April 2023 all-equity acquisition of VIVO Cannabis expanded the combined entity to over CA$50M in annual revenue and added the Beacon Medical and Wildlife brands for international markets. As of Q1 2026, international medical cannabis represented 56% of total revenue and was growing 83% year-over-year. The company employs 101-250 staff, is virtually debt-free with $9.9M in cash, and recently achieved positive adjusted EBITDA under a newly appointed interim CEO.

MediPharm Labs firmographics

Firmographics
Name
MediPharm Labs
Legal name
MediPharm Labs Corp.
Website
https://medipharmlabs.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Short description
MediPharm Labs is a Canadian GMP-certified pharmaceutical cannabis extraction and manufacturing company that produces cannabinoid APIs, white-label products, and branded consumer goods for licensed producers, provincial retailers, and international medical markets across 10 countries.
Ownership category
akta.pro rank

MediPharm Labs industry classification

Industry
Product category
Pharmaceutical Cannabis Manufacturing
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Cannabis extraction services
  • Pharmaceutical cannabis manufacturing
  • GMP-certified cannabis API
  • White label cannabis production
  • Medical cannabis distribution

Where MediPharm Labs is headquartered

Location

Headquarters

HQ city
Barrie
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

MediPharm Labs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. GMP Cannabis API Wholesale: Bulk wholesale offerings including concentrate, distillate, and isolate products in various cannabinoid ratios sold to licensed producers, pharmaceutical companies, cosmetics, food & beverage, and nutraceutical companies.
  2. White Label Production: Custom extraction, distillation, formulation, sensory testing, packaging, labelling, and distribution services for white label clients including licensed producers.
  3. Branded Consumer Products: Pharma-quality branded products including formulated oils (CBD25, CBD50, CBD100, THC30, CBN1:2), soft chews, capsules, vapes, and inhalers sold through Canadian provincial retailers and medical channels.
  4. Clinical Trial Materials: Supply of GMP-certified cannabis products for clinical trials including regulatory support documentation for Health Canada and international clinical trial applications.
  5. International Medical Cannabis: Export of GMP-certified medicinal cannabis products including oils, tinctures, metered dose inhalers, and dried flower to international markets including Australia, Germany, France, Brazil, New Zealand, and Costa Rica.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractB2B wholesale and white label production services
Unit PricingPay-as-you-goBranded consumer products through provincial retailers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

MediPharm Labs product offering

Product offering

Core offering

MediPharm Labs is a pharmaceutical manufacturer specializing in GMP-certified cannabis extraction, purification, and formulation, producing bulk wholesale cannabinoid active pharmaceutical ingredients (API), distillates, and isolates. The company offers white label extraction, distillation, formulation, packaging, and distribution services to licensed producers, and sells its own branded line of formulated oils, soft chews, capsules, vapes, and metered-dose inhalers through Canadian provincial retailers and international medical cannabis channels.

Differentiator

Problem solved

Functional benefit

Brands

  • Beacon Medical: Medical cannabis brand serving international markets including Germany and New Zealand
  • Wildlife

Products and services

  • GMP Cannabis API
  • White Label Cannabis Production
  • MediPharm Labs Branded Consumer Cannabis Products

Quantifiable outcome

  • First Drug Establishment License holder in North America for cannabis API sales
  • +3 more outcomes

Companies that use MediPharm Labs

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles4 records

MediPharm Labs technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

MediPharm Labs partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Remidose LATAM SRLcoreChannel Partner/ Reseller/ Distributor · 13 January 2026Definitive supply agreement for export of GMP-certified medicinal cannabis products including oils, tinctures, metered dose inhalers, and dried flower into Costa Rica's newly opened medical cannabis market. Remidose LATAM holds full licensing and authorization from Costa Rican health authorities. Costa Rica's market is projected to exceed US$35 million annually.
  • International Medicinal Cannabis OrganizationcoreChannel Partner/ Reseller/ Distributor · 4 December 2025Production agreement with an international medicinal cannabis organization for MediPharm's first shipment to France, marking entry into Europe's emerging medical cannabis market. The agreement enables MediPharm to meet strict European regulatory standards while expanding global footprint.
  • VIVO Cannabis Inc.coreStrategic or Co-development Partner · 1 April 2023MediPharm Labs completed acquisition of VIVO Cannabis Inc. in an all-equity transaction, creating a combined entity with expanded international and Canadian market presence. The ownership ratio is approximately 73.1% for MediPharm shareholders and 26.9% for VIVO shareholders. Deal includes integration of VIVO's brands and operations with targeted annual synergies of CA$7-9 million.
  • McMaster UniversitycoreStrategic or Co-development PartnerMediPharm Labs has partnered with McMaster University for multiple approved clinical trials in indications including depression-related sleep disorders, post-surgical pain treatment, and opioid sparing in chronic pain. The partnership includes provision of clinical trial materials with regulatory support documentation for Health Canada submissions.
  • University Health Network (Toronto)coreStrategic or Co-development PartnerAcademic partnership with Toronto's University Health Network leveraging MediPharm's pharmaceutical experience with leading healthcare professionals researching cannabis-derived therapies.
  • Loyalist CollegeminorStrategic or Co-development Partner4-year partnership commitment with Loyalist College including access to applied research opportunities, donation of $100,000 of cannabis derivatives towards study, hiring of interns, and hosting annual cohort for educational lectures. Advancing understanding of cannabis-based medicines.
  • Beacon Medical / Wildlife (Germany)coreChannel Partner/ Reseller/ DistributorPartnership with German distributors Beacon Medical and Wildlife for product portfolio expansion in Germany, supporting 14% sequential revenue growth in Q1 2026.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

MediPharm Labs competitors and assessment

Company assessment

Broad incumbents

  • Canopy Growth Corporation: Canadian cannabis producer with global medical cannabis operations and CPG brands. Comparable on GMP manufacturing, branded consumer products, and international distribution, though it is in restructuring and significantly larger than MediPharm.
  • Tilray Brands: Large multi-jurisdiction cannabis operator with cultivation, processing, branded products, and pharma exposure (including Manitoba Harvest and medical cannabis). Comparable to MediPharm on cannabis manufacturing and international medical distribution, though at far greater scale and with a wider product portfolio.
  • Aurora Cannabis: Major Canadian licensed producer with GMP-certified cultivation, processing, and a focus on medical cannabis across Canada and Europe. Comparable on GMP manufacturing, medical cannabis focus, and international regulatory expertise.
  • Cronos Group: Canadian cannabis operator with international footprint and a focus on branded products and cannabinoid research, including a strategic partnership with Altria. Comparable on GMP operations and international medical distribution, though more consumer-brand focused.
  • Jazz Pharmaceuticals (GW Pharmaceuticals): Owns Epidiolex, the first FDA-approved plant-derived cannabinoid prescription drug, and operates GMP-grade cannabis botanical drug substance manufacturing. Comparable on pharma-grade cannabinoid drug manufacturing and clinical/commercial regulatory pathways.

Direct peers

  • OrganiGram Holdings: Canadian licensed producer with GMP-certified manufacturing, branded consumer products, and international medical cannabis operations. Closely comparable in scale, GMP positioning, and medical/consumer split.
  • The Valens Company: Canadian cannabis extraction specialist and white-label manufacturer producing cannabis concentrates, infused beverages, and pharma-grade products. Directly comparable on extraction-led business model, white label services, and B2B cannabis API offerings.
  • VIVO Cannabis (now part of MediPharm): Canadian licensed producer with Canna Farms medical brand and Beacon Medical/Wildlife international brands. Acquired by MediPharm in 2023; now a subsidiary providing direct comparability on cultivation, branded products, and international medical distribution.
  • Charlotte's Web Holdings: CBD-focused branded cannabis wellness products company with cultivation, extraction, and consumer product lines. Comparable on extraction-to-product manufacturing model and branded CBD/THC product portfolio in regulated markets.
  • Clever Leaves: Multi-jurisdiction cannabis operator focused on GMP-certified cultivation, extraction, and B2B API/finished product supply to international markets including Europe, Latin America, and Australia. Closely comparable on B2B pharma-grade cannabis API model and international medical distribution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

MediPharm Labs social profiles

Digital presence

MediPharm Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MediPharm Labs leadership team

Management profile

Number of profiles

Profiles6 records

MediPharm Labs subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

MediPharm Labs funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MediPharm Labs M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MediPharm Labs

What does MediPharm Labs do?

MediPharm Labs is a pharmaceutical manufacturer specializing in GMP-certified cannabis extraction, purification, and formulation, producing bulk wholesale cannabinoid active pharmaceutical ingredients (API), distillates, and isolates. The company offers white label extraction, distillation, formulation, packaging, and distribution services to licensed producers, and sells its own branded line of formulated oils, soft chews, capsules, vapes, and metered-dose inhalers through Canadian provincial retailers and international medical cannabis channels.

Is MediPharm Labs a public or private company?

MediPharm Labs is a public company. It is classified as public and is currently operating.

When was MediPharm Labs founded?

MediPharm Labs was founded in 2017. It employs 101 to 250 people.

Where is MediPharm Labs based?

MediPharm Labs is headquartered in Barrie, Canada, in the North America region.

How does MediPharm Labs make money?

Five revenue lines are on record. GMP Cannabis API Wholesale is the primary driver. The others are white Label Production, branded Consumer Products, clinical Trial Materials and international Medical Cannabis.

Who are MediPharm Labs's main competitors?

Broad incumbents on record are Canopy Growth Corporation, Tilray Brands, Aurora Cannabis, Cronos Group and Jazz Pharmaceuticals (GW Pharmaceuticals). Direct peers are OrganiGram Holdings, The Valens Company, VIVO Cannabis (now part of MediPharm), Charlotte's Web Holdings and Clever Leaves.

Does MediPharm Labs have an API?

No public API is recorded for MediPharm Labs.

What industry is MediPharm Labs in?

MediPharm Labs's product category is Pharmaceutical Cannabis Manufacturing. Its primary akta.pro industry code is HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC), with a secondary code of HLAGAGAL, GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification). Its NAICS code is 325411 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsWhat MediPharm Labs (LABS) Said on Its Q3 Earnings CallMediPharm Labs reported Q3 2026 revenue of CAD 11.8 million, up 18% from the prior quarter, with positive net income for a second consecutive quarter. International sales drove growth, with Germany and the U.K. offsetting pressure in Australia. The company expects recovery to take time.TradingViewLABS: International medical growth lifted revenue 18% QoQ as profitability continuedMediPharm Labs Corp. reported Q3 2026 revenue of CAD 11.8 million, up 18% quarter-over-quarter, driven by Germany and the U.K. The company posted positive net income for the second quarter and positive Adjusted EBITDA for the third, while Australian and reimbursement headwinds persisted.Business & FinancialMedipharm Labs Corp.MediPharm Labs Corp. reported Q3 2026 results with net income and adjusted EBITDA positive for the second and third consecutive quarters, respectively. Net revenue rose 18% to $11.8M, with German revenue up 19% sequentially and 81% year over year. Shares traded up $0.005 to $0.07.Investing.comEarnings call transcript: MediPharm Labs posts stronger Q3 2026 revenueMediPharm Labs reported Q3 2026 revenue of CAD 11.8 million, up 18% sequentially, and posted positive net income for the second consecutive quarter. Adjusted EBITDA was positive CAD 0.4 million for the third straight quarter, with international medical sales driving growth. The company did not issue forward guidance.Business & FinancialMedipharm Labs Reports Q3 2026 Results With Second Consecutive Quarter Of Positive Net Income And 18% Sequential Revenue GrowthMediPharm Labs reported Q3 2026 revenue of $11.8 million, up 18% sequentially, with a second consecutive quarter of positive net income. International medical revenue rose 20% to $6.9 million, and the company's cash increased to $10.1 million. The company will host a conference call on November 12, 2026.The future of tradingMediPharm Labs publishes update to financial calendarMediPharm Labs will release its third-quarter 2026 financial results before markets open on Nov. 12, 2026. Management will host a conference call and webcast at 10 a.m. Eastern time, with a replay available on the company's investor page.Business & FinancialMedipharm Labs Sets Date To Report Third Quarter 2026 Financial ResultsMediPharm Labs will report its third-quarter 2026 financial results on November 12, 2026, and host a conference call and webcast at 10:00 a.m. Eastern time. The company, a cannabis concentrate and API manufacturer, also announced a forward-looking statement regarding its foreign drug manufacturing site registration with the US FDA.TradingViewMediPharm Labs Corp. (LABS) Gets EU Opinion Supporting 2027 Inhaler CommercializationMediPharm Labs received a positive Article 117 Notified Body Opinion for its inhaler device, supporting a planned 2027 launch as an unlicensed medicinal cannabis product in the UK and selected European markets. The timeline is conditional on country-specific requirements, regulatory acceptance, and import permits, with Blackpoint to lead distribution.American Banking and Market NewsMediPharm Labs Corp. (OTCMKTS:MEDIF) Shares Shorted: Short Interest Up 91.3% in OctoberMediPharm Labs Corp. saw short interest rise 91.3% to 1,907 shares as of October 15th, up from 997 shares on September 30th. The stock opened at $0.04, with a 50-day moving average of $0.05 and a 52-week range of $0.04 to $0.08.Financial PostMediPharm Labs Expands Its International Medical Cannabis Footprint with First CBD Metered-Dose Inhaler Shipment to PanamaMediPharm Labs shipped its first CBD metered-dose inhaler to Panama's Adeiwa Pharma, marking its first commercial sale in the country. The product is expected to reach patients this month under an import authorization exception. The company cites a projected Latin American medical cannabis market growth to $581.5 million by 2030.